Grail's cancer blood test faces FDA regulatory review
Summarised from 2 outlets · Updated 23 Sept, 22:44 · Archive
A blood test designed to detect multiple cancers in healthy people is undergoing FDA regulatory review.
Grail's blood test aims to identify signs of multiple cancers in asymptomatic individuals. The test is facing its first major regulatory hurdle with the U.S. Food and Drug Administration.
How it is being reported
- Grail's cancer blood test faces high-stakes FDA reviewClickorlando · 23 Sept, 14:22
- Grail's cancer blood test faces high-stakes FDA reviewNews4Jax · 23 Sept, 14:22
In this story: Grail · FDA · United States
This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem
Comments (0)